Evidence map›Paper›PMID 41547689›Full record

ReviewClinical and experimental medicine2026

Long non-coding RNAs and therapeutic resistance in multiple myeloma: from molecular insights to clinical applications.

Mohamad Hosein Safari, Najma Farahani, Amirhossein Faghih Ojaroodi, Amirali Ebrahimpour, William C Cho, Fateme Zare Khormizi, Alireza Mafi, Rasoul Raesi, Maryam Mohammad-Sadeghipour, Mina Alimohammadi and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mohamad Hosein SafariDepartment of Internal Medicine, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Najma FarahaniFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, Faculty of Medicine, TeMs.C., Islamic Azad University, Tehran, Iran.
Amirhossein Faghih OjaroodiStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Amirali EbrahimpourStudent Research Committee, Varastegan Institute for Medical Sciences, Mashhad, Iran.
William C ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.
Fateme Zare KhormiziDepartment of Biology, Yazd University, Yazd, Iran.
Alireza MafiDepartment of Genetics and Biochemistry, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Rasoul RaesiDepartment of Public Health, School of Health, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran.
Maryam Mohammad-SadeghipourOccupational Safety and Health Research Center, NICICO, World Safety Organization, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Maryam.ms160@gmail.com.
Mina AlimohammadiDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mina.alimohammadi11@gmail.com.
Kiavash HushmandiNephrology and Urology Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. houshmandi.kia7@ut.ac.ir.
Mehrdad HashemiFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, Faculty of Medicine, TeMs.C., Islamic Azad University, Tehran, Iran. mhashemi@iautmu.ac.ir.
Afshin TaheriazamFarhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, Faculty of Medicine, TeMs.C., Islamic Azad University, Tehran, Iran. a.taheriazam@iautmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a complex hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. Despite advances in therapy, resistance remains a significant obstacle to curing the disease. Long non-coding RNAs (lncRNAs), a broad family of regulatory RNA molecules, have recently been recognized as important players in MM biology, influencing disease progression and treatment response. This review explores current insights into the diverse roles of lncRNAs in MM, focusing on their involvement in key molecular processes, including miRNA sponging, epigenetic regulation, apoptosis, and interactions with signaling pathways such as PI3K/Akt and STAT3. Additionally, the review evaluates emerging treatment strategies targeting lncRNAs, including RNA-based therapeutics, CRISPR/Cas9 technology, and exosome-mediated delivery systems, assessing their potential to overcome drug resistance and improve clinical outcomes. By integrating molecular research with clinical implications, this review emphasizes the promise of lncRNAs as biomarkers and therapeutic targets in MM and offers a framework for future research and development.

Indexed as

Drug Resistance, NeoplasmMultiple MyelomaRNA, Long NoncodingAnimalsApoptosisGene Expression Regulation, NeoplasticHumansMicroRNAsSignal TransductionMicroRNAsRNA, Long NoncodingCRISPR/Cas9Drug resistanceLncRNA-targeted therapyLong non-coding RNAMultiple myelomaSignaling pathways

Identifiers

PMID41547689
PMCPMC12847185

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.